Galera Therapeutics, Inc. (GRTXD) Stock Price & Analysis
Galera Therapeutics, Inc. (GRTXD) rose 0.00% to USD 17.5 as of July 25, 2026 at 04:57 UTC, according to Nexqual real-time market data.
GRTXD last closed at USD 17.5; the session ranged USD 15.25–15.25 on volume of 3 shares. Market capitalization is $18.18M, with a 52-week range of USD 3–30 (OQB). Source: Nexqual, July 25, 2026 at 04:57 UTC.
Key Statistics (as of July 25, 2026 at 04:57 UTC)
| Price | USD 17.5 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 17.5 |
| Open | USD 15.25 |
| Day Range | USD 15.25 – 15.25 |
| 52-Week Range | USD 3 – 30 |
| Volume | 3 shares |
| Market Cap | $18.18M |
| Exchange | OQB |
Technical Analysis (GRTXD)
Nexqual's technical model rates GRTXD "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 04:57 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.16 (neutral) |
| vs SMA50 | Below (USD 18.31) |
| MACD | -0.34 (negative) |
Analyst Ratings (GRTXD)
Wall Street analysts rate GRTXD "None", per Nexqual as of July 25, 2026 at 04:57 UTC.
| Consensus Rating | None |
|---|
Earnings (GRTXD)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -66 vs est -79.44 ▲ beat |
| 2023-06-30 | USD -96 vs est -75.66 ▼ miss |
| 2023-03-31 | USD -100 vs est -85.95 ▼ miss |
| 2022-12-31 | USD -116 vs est -101.03 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:57 UTC.
Financials & Fundamentals (GRTXD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 5.31 |
| Total Cash | $5.50M |
| Total Debt | $0 |
| Free Cash Flow | $-2.76M |
Source: Nexqual, July 25, 2026 at 04:57 UTC.
Financial Health Score (GRTXD)
Nexqual rates Galera Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Mixed — No data |
Ownership (GRTXD)
| Insider Ownership | +52.62% |
|---|---|
| Institutional Ownership | +7.71% |
| Shares Outstanding | 1.04M |
| Float | 404,861 |
| Short % of Float | +4.75% |
Source: Nexqual, July 25, 2026 at 04:57 UTC.
Leadership (GRTXD)
Galera Therapeutics, Inc. is led by John Mel Sorensen (age 68), CEO, President & Chairman, per Nexqual as of July 25, 2026 at 04:57 UTC.
| CEO, President & Chairman | John Mel Sorensen (age 68) |
|---|
From Galera Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer.
- The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC).
- It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| BFRI | Biofrontera Inc. | USD 1.09 | ▲ 0.93% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:57 UTC. This page is informational and not investment advice.